Allergic respiratory diseases are amongst the most common allergies worldwide and constitute major public health and economic problem for their morbidity and impact on quality of life. A substantial documented study has been attributed to unraveling the mechanisms of respiratory allergic and inflammatory diseases, but still, a lot of questions are elusive. The discovery of new cytokines, molecular signaling pathways, and new functions of cells in innate and adaptive immunity may influence the understanding of innate and adaptive immune crosstalk in health and diseases. Now, therapeutic antibodies used in clinical can improve airway inflammation and remodel via intervening in the various stages in the pathogenesis of allergy. In addition, a number of potential biological agents such as antibodies targeting the alarmins, type 2 cytokines, and inflammatory factors are in development. Thus, the new discoveries in allergy-related immunology studies and emerging biological therapies are drastically improving the treatment of allergic respiratory diseases.
This topic aims to track the latest immunological advances in the underlying pathophysiology of allergic respiratory diseases. We hope this research topic can provide a forum to advance research on the contribution of allergic respiratory diseases to the genesis and development of chronic diseases as well as to explore innovative pharmacological interventions in the attempt to achieve a beneficial impact on respiratory allergy and inflammation.
This research topic welcomes original research, reviews, and methods that covers asthma, rhinology, allergic rhinitis, but are not limited to:
1. New antibody-based therapy targeted on alarmins, Th2 cytokines, and inflammatory factors in respiratory
allergic diseases.
2. Epithelial barrier dysfunction in allergic airway inflammation.
3. Epigenetic regulation of T cell, B cell, Innate lymphocytes, and other immune cells in lung chronic
inflammation.
4. Host immune response against allergens and environmental pollutants.
5. Role of the mucosal microbiome in lung and airway, and the interaction with mucosal immune cells.
6. Secreted immune mediators within the lung and airway tract.
7. Vaccine and drug delivery systems targeting the mucosa.
8. Lung fibrosis and underlying molecular and immune mechanisms.
Allergic respiratory diseases are amongst the most common allergies worldwide and constitute major public health and economic problem for their morbidity and impact on quality of life. A substantial documented study has been attributed to unraveling the mechanisms of respiratory allergic and inflammatory diseases, but still, a lot of questions are elusive. The discovery of new cytokines, molecular signaling pathways, and new functions of cells in innate and adaptive immunity may influence the understanding of innate and adaptive immune crosstalk in health and diseases. Now, therapeutic antibodies used in clinical can improve airway inflammation and remodel via intervening in the various stages in the pathogenesis of allergy. In addition, a number of potential biological agents such as antibodies targeting the alarmins, type 2 cytokines, and inflammatory factors are in development. Thus, the new discoveries in allergy-related immunology studies and emerging biological therapies are drastically improving the treatment of allergic respiratory diseases.
This topic aims to track the latest immunological advances in the underlying pathophysiology of allergic respiratory diseases. We hope this research topic can provide a forum to advance research on the contribution of allergic respiratory diseases to the genesis and development of chronic diseases as well as to explore innovative pharmacological interventions in the attempt to achieve a beneficial impact on respiratory allergy and inflammation.
This research topic welcomes original research, reviews, and methods that covers asthma, rhinology, allergic rhinitis, but are not limited to:
1. New antibody-based therapy targeted on alarmins, Th2 cytokines, and inflammatory factors in respiratory
allergic diseases.
2. Epithelial barrier dysfunction in allergic airway inflammation.
3. Epigenetic regulation of T cell, B cell, Innate lymphocytes, and other immune cells in lung chronic
inflammation.
4. Host immune response against allergens and environmental pollutants.
5. Role of the mucosal microbiome in lung and airway, and the interaction with mucosal immune cells.
6. Secreted immune mediators within the lung and airway tract.
7. Vaccine and drug delivery systems targeting the mucosa.
8. Lung fibrosis and underlying molecular and immune mechanisms.
